Stage I Testicular Germ Cell Tumors After Orchiectomy: Surveillance, Adjuvant Therapy, and Risk-Adapted Follow-Up

Authored by Natalia Gandur, published on 2026-07-10 11:32:19.0

This algorithm is broadly aligned with contemporary stage I testicular GCT management: confirm true clinical stage I with appropriate post-orchiectomy marker kinetics and imaging, then select surveillance vs limited adjuvant therapy based on histology and relapse risk. It appropriately favors surveillance for most stage I seminoma and uses LVI to risk-adapt stage I NSGCT, with adjuvant BEP x1 as a common relapse-reduction option. Follow-up recommendations are consistent with modern efforts to minimize radiation (MRI as an alternative to CT) and to avoid routine PET in surveillance.

  1. Post-orchiectomy testicular germ cell tumor: confirm pathology, markers, imaging, and clinical stage
    Confirm pathology, post-orchiectomy tumor marker kinetics, imaging, clinical stage, fertility goals, and surveillance feasibility. Begin after radical inguinal orchiectomy for testicular germ cell tumor. Confirm: - Histology: seminoma, non-seminoma, or mixed germ cell tumor. - Presence of any non-seminomatous component. - AFP, beta-hCG, and LDH before orchiectomy and after orchiectomy. - Expected marker normalization according to marker half-life. - CT abdomen/pelvis or MRI where appropriate. - Chest imaging according to clinical context and local practice. - No radiographic metastatic disease. - Pathology features: tumor size, rete testis invasion, lymphovascular invasion, embryonal carcinoma component, teratoma, somatic-type malignant transformation, spermatic cord involvement, margins if relevant. - ECOG performance status. - Renal function and baseline labs if chemotherapy may be considered. - Fertility goals, sperm banking status, testosterone symptoms, testicular prosthesis preference, psychosocial needs, and ability to comply with surveillance. This pathway applies only to clinical stage I disease after orchiectomy.
    • Clinical stage I confirmed and markers normalizing?
      Proceed only if imaging shows no metastatic disease and AFP/beta-hCG normalize appropriately after orchiectomy. Clinical stage I requires no radiographic evidence of metastatic disease and appropriate post-orchiectomy tumor marker decline. If AFP or beta-hCG remain unequivocally elevated, rise, or fail to normalize after orchiectomy, do not manage as routine stage I disease. If markers remain persistently elevated: - Repeat markers to confirm the trend. - Consider expected marker half-life and non-malignant causes of mild AFP elevation. - Reassess imaging. - Evaluate the contralateral testis if clinically indicated. - If marker elevation is unequivocal and contralateral tumor is excluded, route to metastatic germ cell tumor management according to IGCCCG risk group. Stable, slightly elevated AFP or beta-hCG may require careful repeat testing and clinical correlation before committing to systemic treatment.
      • NO
        • Persistent/rising AFP or beta-hCG, or metastatic disease -> metastatic GCT pathway
      • YES
        • Histology: seminoma vs non-seminoma / mixed GCT
          Separate pure seminoma from non-seminoma or mixed GCT; AFP elevation should be managed as non-seminoma biology. Histology determines the post-orchiectomy management pathway. Pure seminoma: - Route to stage I seminoma management. - Surveillance is preferred for most patients if resources and compliance are adequate. - Carboplatin AUC 7 x1 may be considered when adjuvant therapy is chosen. - Radiotherapy should not be routine. Non-seminoma / mixed GCT: - Route to stage I non-seminoma management. - Risk-adapt primarily by lymphovascular invasion. - Surveillance and adjuvant BEP x1 are the main options. - RPLND has a limited role and should be reserved for highly selected patients in expert centers. If AFP is elevated, manage as non-seminoma biology even if seminoma is reported, because pure seminoma should not produce AFP.
          • Seminoma stage I
            Surveillance is preferred for most patients; carboplatin AUC 7 x1 is an option if adjuvant therapy is chosen; radiotherapy should not be routine. Management options for clinical stage I seminoma include surveillance and adjuvant carboplatin. Retroperitoneal radiotherapy has an extremely limited role. Preferred approach: - Surveillance if resources are available and the patient is willing and able to comply. Why surveillance is preferred: - Most patients are cured with orchiectomy alone. - Cancer-specific survival is over 99% with surveillance when relapse is detected and treated appropriately. - Adjuvant therapy would overtreat most patients. Risk considerations: - Relapse risk may be influenced by tumor size and rete testis invasion, but risk-adapted decision-making is imperfect. - Patients with higher relapse concern may consider adjuvant carboplatin after shared discussion. Adjuvant chemotherapy option: - Carboplatin AUC 7 x1 if adjuvant chemotherapy is selected. Radiotherapy: - Do not routinely perform adjuvant radiotherapy. - Reserve radiotherapy only for highly selected patients who are unsuitable for systemic chemotherapy, recognizing late secondary malignancy risk. Clinical framing: The goal is to maintain near-universal cure while minimizing unnecessary treatment and long-term toxicity.
            • Seminoma stage I: surveillance preferred if resources and compliance are adequate
              Active surveillance with clinical assessment, tumor markers, and scheduled abdominopelvic MRI/CT. Surveillance is active management, not absence of care. Best fit: - Stage I seminoma. - Markers normalized after orchiectomy. - No radiographic metastatic disease. - Patient can comply with follow-up. - Patient prefers to avoid adjuvant toxicity. Minimum follow-up framework: - Tumor markers ± doctor visit: - Year 1: 2 times. - Year 2: 2 times. - Year 3: 2 times. - Years 4 and 5: once. - After 5 years: survivorship care plan. - Abdominopelvic MRI or CT: - Year 1: 2 times. - Year 2: 2 times. - Year 3: once at 36 months. - Years 4 and 5: once at 60 months. - Chest X-ray is not routine in the EAU minimal follow-up table for stage I seminoma. Imaging considerations: - MRI can be used instead of CT in experienced centers to reduce radiation exposure. - FDG-PET/CT is not recommended during surveillance. Counseling: - Most relapses occur in the retroperitoneum. - Relapse is usually salvageable with stage-adapted therapy. - Surveillance requires adherence; if adherence is not feasible, adjuvant carboplatin may be considered.
              • SURVEILLANCE
                • Seminoma surveillance: markers + visits + abdominopelvic MRI/CT schedule
                  • FOLLOW-UP
                    • CARE PLAN
                      • Fertility, testosterone, prosthesis, psychosocial care, and survivorship plan
                        Address sperm banking, testosterone symptoms, prosthesis, psychosocial needs, late toxicity, cardiovascular risk, and survivorship plan. Survivorship begins at diagnosis. Before adjuvant therapy: - Discuss fertility goals. - Offer sperm banking before chemotherapy or radiotherapy when feasible. - Discuss testicular prosthesis if not already addressed. - Document baseline sexual health and testosterone-related symptoms when relevant. - Review psychosocial distress, body image, work, relationships, and financial/logistical barriers to follow-up. During follow-up: - Screen and manage hypertension. - Screen and manage hyperlipidemia. - Assess testosterone deficiency symptoms. - Encourage smoking cessation and healthy lifestyle. - Counsel on hearing, neuropathy, pulmonary symptoms, renal function, cardiovascular risk, and second malignancy risk when relevant to prior therapy. - Provide a written survivorship plan when transitioning out of specialist follow-up. Implementation note: This node is essential because many patients are young and have decades of life expectancy after cure.
                    • Follow-up framework: markers, clinical assessment, MRI/CT, minimize radiation exposure
                      Use risk- and treatment-adapted follow-up with markers, clinical assessment, MRI/CT, and radiation minimization. Follow-up should be adapted to histology, initial management, relapse risk, and prior treatment. General principles: - Use structured follow-up rather than informal monitoring. - Include tumor markers: AFP, beta-hCG, LDH. - Include clinical assessment. - Use abdominopelvic MRI or CT according to guideline schedule and local expertise. - Minimize radiation exposure when possible. - MRI can replace CT in experienced centers. - FDG-PET/CT is not recommended during surveillance. - After 5 years, routine imaging is generally not recommended; focus shifts to survivorship and symptom-triggered evaluation. Seminoma stage I minimal follow-up: - Markers ± visit: 2 times in year 1, 2 times in year 2, 2 times in year 3, once in years 4–5. - Abdominopelvic MRI/CT: 2 times in year 1, 2 times in year 2, once at 36 months, once at 60 months. Non-seminoma stage I on active surveillance: - Markers ± visit: 4 times in year 1, 4 times in year 2, 2 times in year 3, 1–2 times in years 4–5. - Chest X-ray: 2 times in year 1, 2 times in year 2; consider later imaging according to risk and care plan. - Abdominopelvic MRI/CT: 2 times in year 1, at 24 months, once at 36 months, and once at 60 months depending on risk and local practice. - For LVI-positive patients, some groups recommend more frequent early marker assessment and additional imaging. After adjuvant treatment: - Follow treatment-adapted protocols; markers/visits are generally more frequent in the first two years. - Continue survivorship-focused care after routine oncologic imaging ends.
                      • RELAPSE
                        • If relapse detected: stage-adapted salvage / metastatic GCT pathway
                          If relapse occurs, restage and route to stage-adapted salvage or metastatic GCT pathway. This stage I pathway should not embed a full metastatic treatment algorithm. If relapse is suspected: - Repeat AFP, beta-hCG, and LDH. - Confirm with appropriate imaging. - Define relapse pattern: retroperitoneal, thoracic, visceral, marker-only, local, or multifocal. - Confirm histology context: seminoma versus non-seminoma. - Assess prior adjuvant therapy: surveillance only, carboplatin, BEP x1, radiotherapy, or RPLND. - Evaluate timing of relapse. - Route to stage-adapted metastatic GCT management. - Consider referral to a germ cell tumor expert center, especially for relapse after adjuvant chemotherapy, late relapse, teratoma, somatic-type malignant transformation, or complex surgical questions. Do not manage relapse as a simple continuation of stage I surveillance.
                      • NUANCE
                        • Clinical nuance: avoid overtreatment; surveillance requires adherence; treatment decisions must include late toxicity
                          Avoid overtreatment, preserve cure, ensure surveillance adherence, and incorporate fertility and late toxicity into every decision. Key clinical nuances: 1. Surveillance is active management. It is appropriate only if the patient can adhere to visits, tumor markers, and imaging. 2. Cure is expected across strategies. The decision is mainly about relapse-risk reduction versus overtreatment and late toxicity. 3. Seminoma stage I: Surveillance is preferred for most. Carboplatin AUC 7 x1 is reasonable if adjuvant therapy is chosen. Radiotherapy should be avoided routinely. 4. NSGCT stage I: LVI is the key risk-adaptive variable. LVI-negative patients should generally be offered surveillance if compliant. LVI-positive patients should discuss BEP x1 or surveillance. 5. RPLND: Do not use routinely. Reserve for selected NSGCT patients in expert centers. 6. Markers: Persistent or rising AFP or beta-hCG after orchiectomy should not be treated as ordinary stage I disease. 7. Fertility and survivorship: Sperm banking, testosterone, psychosocial care, cardiovascular risk, hearing, neuropathy, renal function, pulmonary risk, and secondary malignancy risk should be considered before treatment selection. 8. Imaging: Minimize unnecessary radiation exposure. MRI can replace CT in experienced centers. FDG-PET/CT is not recommended for routine surveillance.
              • ADJUVANT
                • Carboplatin AUC 7 x 1 if adjuvant therapy is chosen
                  Adjuvant carboplatin is an alternative to surveillance in selected patients with clinical stage I seminoma. Dose: - Carboplatin AUC 7 x1. Best fit: - Patient prefers relapse-risk reduction over surveillance alone. - Surveillance adherence is uncertain or not feasible. - Patient has significant anxiety about surveillance after balanced counseling. - Higher relapse-risk features are present and the patient chooses adjuvant therapy. Before treatment: - Confirm pure seminoma histology. - Confirm normalized markers. - Confirm no metastatic disease. - CBC. - Renal function for carboplatin dosing. - Review fertility goals and sperm banking. - Discuss acute toxicity and uncertainty about very long-term toxicity after adjuvant carboplatin. Follow-up: - Follow-up after adjuvant carboplatin should remain similar to seminoma surveillance because relapses can still occur, often in the retroperitoneum and sometimes later. Avoid: - Presenting carboplatin as mandatory for stage I seminoma.- Using adjuvant carboplatin for non-seminoma.
                  • SELECTED
                    • Radiotherapy: generally avoid; reserve for highly selected patients
                      Do not routinely use adjuvant radiotherapy for stage I seminoma; reserve only for highly selected patients. Adjuvant radiotherapy has an extremely limited role in clinical stage I seminoma. Do not routinely perform adjuvant radiotherapy. Reserve only for highly selected patients: - Unsuitable for surveillance. - Unsuitable for systemic chemotherapy, including adjuvant carboplatin. - Fully informed about late toxicity and second malignancy risk. Clinical concern: Radiotherapy can reduce relapse risk but exposes young patients with long life expectancy to avoidable late toxicity, including secondary non-germ cell malignancies within the radiation field. This branch should be visually de-emphasized.
                      • FOLLOW-UP
                        • CARE PLAN
                          • Fertility, testosterone, prosthesis, psychosocial care, and survivorship plan
                            Address sperm banking, testosterone symptoms, prosthesis, psychosocial needs, late toxicity, cardiovascular risk, and survivorship plan. Survivorship begins at diagnosis. Before adjuvant therapy: - Discuss fertility goals. - Offer sperm banking before chemotherapy or radiotherapy when feasible. - Discuss testicular prosthesis if not already addressed. - Document baseline sexual health and testosterone-related symptoms when relevant. - Review psychosocial distress, body image, work, relationships, and financial/logistical barriers to follow-up. During follow-up: - Screen and manage hypertension. - Screen and manage hyperlipidemia. - Assess testosterone deficiency symptoms. - Encourage smoking cessation and healthy lifestyle. - Counsel on hearing, neuropathy, pulmonary symptoms, renal function, cardiovascular risk, and second malignancy risk when relevant to prior therapy. - Provide a written survivorship plan when transitioning out of specialist follow-up. Implementation note: This node is essential because many patients are young and have decades of life expectancy after cure.
                        • Follow-up framework: markers, clinical assessment, MRI/CT, minimize radiation exposure
                          Use risk- and treatment-adapted follow-up with markers, clinical assessment, MRI/CT, and radiation minimization. Follow-up should be adapted to histology, initial management, relapse risk, and prior treatment. General principles: - Use structured follow-up rather than informal monitoring. - Include tumor markers: AFP, beta-hCG, LDH. - Include clinical assessment. - Use abdominopelvic MRI or CT according to guideline schedule and local expertise. - Minimize radiation exposure when possible. - MRI can replace CT in experienced centers. - FDG-PET/CT is not recommended during surveillance. - After 5 years, routine imaging is generally not recommended; focus shifts to survivorship and symptom-triggered evaluation. Seminoma stage I minimal follow-up: - Markers ± visit: 2 times in year 1, 2 times in year 2, 2 times in year 3, once in years 4–5. - Abdominopelvic MRI/CT: 2 times in year 1, 2 times in year 2, once at 36 months, once at 60 months. Non-seminoma stage I on active surveillance: - Markers ± visit: 4 times in year 1, 4 times in year 2, 2 times in year 3, 1–2 times in years 4–5. - Chest X-ray: 2 times in year 1, 2 times in year 2; consider later imaging according to risk and care plan. - Abdominopelvic MRI/CT: 2 times in year 1, at 24 months, once at 36 months, and once at 60 months depending on risk and local practice. - For LVI-positive patients, some groups recommend more frequent early marker assessment and additional imaging. After adjuvant treatment: - Follow treatment-adapted protocols; markers/visits are generally more frequent in the first two years. - Continue survivorship-focused care after routine oncologic imaging ends.
                          • RELAPSE
                            • If relapse detected: stage-adapted salvage / metastatic GCT pathway
                              If relapse occurs, restage and route to stage-adapted salvage or metastatic GCT pathway. This stage I pathway should not embed a full metastatic treatment algorithm. If relapse is suspected: - Repeat AFP, beta-hCG, and LDH. - Confirm with appropriate imaging. - Define relapse pattern: retroperitoneal, thoracic, visceral, marker-only, local, or multifocal. - Confirm histology context: seminoma versus non-seminoma. - Assess prior adjuvant therapy: surveillance only, carboplatin, BEP x1, radiotherapy, or RPLND. - Evaluate timing of relapse. - Route to stage-adapted metastatic GCT management. - Consider referral to a germ cell tumor expert center, especially for relapse after adjuvant chemotherapy, late relapse, teratoma, somatic-type malignant transformation, or complex surgical questions. Do not manage relapse as a simple continuation of stage I surveillance.
                          • NUANCE
                            • Clinical nuance: avoid overtreatment; surveillance requires adherence; treatment decisions must include late toxicity
                              Avoid overtreatment, preserve cure, ensure surveillance adherence, and incorporate fertility and late toxicity into every decision. Key clinical nuances: 1. Surveillance is active management. It is appropriate only if the patient can adhere to visits, tumor markers, and imaging. 2. Cure is expected across strategies. The decision is mainly about relapse-risk reduction versus overtreatment and late toxicity. 3. Seminoma stage I: Surveillance is preferred for most. Carboplatin AUC 7 x1 is reasonable if adjuvant therapy is chosen. Radiotherapy should be avoided routinely. 4. NSGCT stage I: LVI is the key risk-adaptive variable. LVI-negative patients should generally be offered surveillance if compliant. LVI-positive patients should discuss BEP x1 or surveillance. 5. RPLND: Do not use routinely. Reserve for selected NSGCT patients in expert centers. 6. Markers: Persistent or rising AFP or beta-hCG after orchiectomy should not be treated as ordinary stage I disease. 7. Fertility and survivorship: Sperm banking, testosterone, psychosocial care, cardiovascular risk, hearing, neuropathy, renal function, pulmonary risk, and secondary malignancy risk should be considered before treatment selection. 8. Imaging: Minimize unnecessary radiation exposure. MRI can replace CT in experienced centers. FDG-PET/CT is not recommended for routine surveillance.
                  • FOLLOW-UP
                    • CARE PLAN
                      • Fertility, testosterone, prosthesis, psychosocial care, and survivorship plan
                        Address sperm banking, testosterone symptoms, prosthesis, psychosocial needs, late toxicity, cardiovascular risk, and survivorship plan. Survivorship begins at diagnosis. Before adjuvant therapy: - Discuss fertility goals. - Offer sperm banking before chemotherapy or radiotherapy when feasible. - Discuss testicular prosthesis if not already addressed. - Document baseline sexual health and testosterone-related symptoms when relevant. - Review psychosocial distress, body image, work, relationships, and financial/logistical barriers to follow-up. During follow-up: - Screen and manage hypertension. - Screen and manage hyperlipidemia. - Assess testosterone deficiency symptoms. - Encourage smoking cessation and healthy lifestyle. - Counsel on hearing, neuropathy, pulmonary symptoms, renal function, cardiovascular risk, and second malignancy risk when relevant to prior therapy. - Provide a written survivorship plan when transitioning out of specialist follow-up. Implementation note: This node is essential because many patients are young and have decades of life expectancy after cure.
                    • Follow-up framework: markers, clinical assessment, MRI/CT, minimize radiation exposure
                      Use risk- and treatment-adapted follow-up with markers, clinical assessment, MRI/CT, and radiation minimization. Follow-up should be adapted to histology, initial management, relapse risk, and prior treatment. General principles: - Use structured follow-up rather than informal monitoring. - Include tumor markers: AFP, beta-hCG, LDH. - Include clinical assessment. - Use abdominopelvic MRI or CT according to guideline schedule and local expertise. - Minimize radiation exposure when possible. - MRI can replace CT in experienced centers. - FDG-PET/CT is not recommended during surveillance. - After 5 years, routine imaging is generally not recommended; focus shifts to survivorship and symptom-triggered evaluation. Seminoma stage I minimal follow-up: - Markers ± visit: 2 times in year 1, 2 times in year 2, 2 times in year 3, once in years 4–5. - Abdominopelvic MRI/CT: 2 times in year 1, 2 times in year 2, once at 36 months, once at 60 months. Non-seminoma stage I on active surveillance: - Markers ± visit: 4 times in year 1, 4 times in year 2, 2 times in year 3, 1–2 times in years 4–5. - Chest X-ray: 2 times in year 1, 2 times in year 2; consider later imaging according to risk and care plan. - Abdominopelvic MRI/CT: 2 times in year 1, at 24 months, once at 36 months, and once at 60 months depending on risk and local practice. - For LVI-positive patients, some groups recommend more frequent early marker assessment and additional imaging. After adjuvant treatment: - Follow treatment-adapted protocols; markers/visits are generally more frequent in the first two years. - Continue survivorship-focused care after routine oncologic imaging ends.
                      • RELAPSE
                        • If relapse detected: stage-adapted salvage / metastatic GCT pathway
                          If relapse occurs, restage and route to stage-adapted salvage or metastatic GCT pathway. This stage I pathway should not embed a full metastatic treatment algorithm. If relapse is suspected: - Repeat AFP, beta-hCG, and LDH. - Confirm with appropriate imaging. - Define relapse pattern: retroperitoneal, thoracic, visceral, marker-only, local, or multifocal. - Confirm histology context: seminoma versus non-seminoma. - Assess prior adjuvant therapy: surveillance only, carboplatin, BEP x1, radiotherapy, or RPLND. - Evaluate timing of relapse. - Route to stage-adapted metastatic GCT management. - Consider referral to a germ cell tumor expert center, especially for relapse after adjuvant chemotherapy, late relapse, teratoma, somatic-type malignant transformation, or complex surgical questions. Do not manage relapse as a simple continuation of stage I surveillance.
                      • NUANCE
                        • Clinical nuance: avoid overtreatment; surveillance requires adherence; treatment decisions must include late toxicity
                          Avoid overtreatment, preserve cure, ensure surveillance adherence, and incorporate fertility and late toxicity into every decision. Key clinical nuances: 1. Surveillance is active management. It is appropriate only if the patient can adhere to visits, tumor markers, and imaging. 2. Cure is expected across strategies. The decision is mainly about relapse-risk reduction versus overtreatment and late toxicity. 3. Seminoma stage I: Surveillance is preferred for most. Carboplatin AUC 7 x1 is reasonable if adjuvant therapy is chosen. Radiotherapy should be avoided routinely. 4. NSGCT stage I: LVI is the key risk-adaptive variable. LVI-negative patients should generally be offered surveillance if compliant. LVI-positive patients should discuss BEP x1 or surveillance. 5. RPLND: Do not use routinely. Reserve for selected NSGCT patients in expert centers. 6. Markers: Persistent or rising AFP or beta-hCG after orchiectomy should not be treated as ordinary stage I disease. 7. Fertility and survivorship: Sperm banking, testosterone, psychosocial care, cardiovascular risk, hearing, neuropathy, renal function, pulmonary risk, and secondary malignancy risk should be considered before treatment selection. 8. Imaging: Minimize unnecessary radiation exposure. MRI can replace CT in experienced centers. FDG-PET/CT is not recommended for routine surveillance.
          • NSGCT / MIXED
            • Non-seminoma stage I: risk-adapt by lymphovascular invasion
              Clinical stage I non-seminoma management should be risk-adapted primarily by lymphovascular invasion. Management options: - Surveillance. - Adjuvant chemotherapy with BEP x1. - RPLND only in highly selected patients and expert centers. Key risk factor: - Lymphovascular invasion is the strongest and most reproducible predictor of relapse. Approximate relapse framing: - About 70% of clinical stage I NSGCT patients are cured with orchiectomy alone. - Relapse risk is substantially higher with LVI present. - Surveillance remains valid if the patient is willing and able to comply. - BEP x1 substantially reduces relapse risk but exposes patients to cisplatin/etoposide/bleomycin toxicity.
              • ASSESS LVI
                • Lymphovascular invasion present?
                  Use LVI to stratify stage I non-seminoma into lower-risk and higher-risk groups. Assess lymphovascular invasion carefully in the orchiectomy specimen. If LVI absent: - Stage IA / lower relapse risk. - Surveillance is preferred if the patient can comply. If LVI present: - Higher relapse risk. - Discuss BEP x1 as preferred adjuvant option, or surveillance after shared decision-making. Additional factors may influence discussion: - Embryonal carcinoma predominance. - Tumor size. - Invasion of testicular hilum. - Teratoma or pure teratoma. - Somatic-type malignant transformation. - Patient ability to comply with surveillance. - Patient preference after discussion of relapse risk and toxicity.
                  • NO
                    • LVI absent / stage IA: surveillance preferred if compliant
                      Surveillance preferred if the patient is willing and able to comply. For clinical stage I non-seminoma without lymphovascular invasion, surveillance is preferred when the patient can comply. Best fit: - pT1 / no vascular invasion. - Markers normalized after orchiectomy. - No metastatic disease on imaging. - Patient accepts structured surveillance. - Patient prefers to avoid immediate chemotherapy toxicity. Adjuvant chemotherapy: - BEP x1 may be offered if the patient is unwilling or unsuitable to undergo surveillance. Counseling: - Surveillance avoids overtreatment in many patients. - Most relapses occur within the first two years. - Relapse is generally salvageable with standard cisplatin-based therapy. - Surveillance requires strict adherence to markers, visits, and imaging.
                      • FOLLOW-UP
                        • CARE PLAN
                          • Fertility, testosterone, prosthesis, psychosocial care, and survivorship plan
                            Address sperm banking, testosterone symptoms, prosthesis, psychosocial needs, late toxicity, cardiovascular risk, and survivorship plan. Survivorship begins at diagnosis. Before adjuvant therapy: - Discuss fertility goals. - Offer sperm banking before chemotherapy or radiotherapy when feasible. - Discuss testicular prosthesis if not already addressed. - Document baseline sexual health and testosterone-related symptoms when relevant. - Review psychosocial distress, body image, work, relationships, and financial/logistical barriers to follow-up. During follow-up: - Screen and manage hypertension. - Screen and manage hyperlipidemia. - Assess testosterone deficiency symptoms. - Encourage smoking cessation and healthy lifestyle. - Counsel on hearing, neuropathy, pulmonary symptoms, renal function, cardiovascular risk, and second malignancy risk when relevant to prior therapy. - Provide a written survivorship plan when transitioning out of specialist follow-up. Implementation note: This node is essential because many patients are young and have decades of life expectancy after cure.
                        • Follow-up framework: markers, clinical assessment, MRI/CT, minimize radiation exposure
                          Use risk- and treatment-adapted follow-up with markers, clinical assessment, MRI/CT, and radiation minimization. Follow-up should be adapted to histology, initial management, relapse risk, and prior treatment. General principles: - Use structured follow-up rather than informal monitoring. - Include tumor markers: AFP, beta-hCG, LDH. - Include clinical assessment. - Use abdominopelvic MRI or CT according to guideline schedule and local expertise. - Minimize radiation exposure when possible. - MRI can replace CT in experienced centers. - FDG-PET/CT is not recommended during surveillance. - After 5 years, routine imaging is generally not recommended; focus shifts to survivorship and symptom-triggered evaluation. Seminoma stage I minimal follow-up: - Markers ± visit: 2 times in year 1, 2 times in year 2, 2 times in year 3, once in years 4–5. - Abdominopelvic MRI/CT: 2 times in year 1, 2 times in year 2, once at 36 months, once at 60 months. Non-seminoma stage I on active surveillance: - Markers ± visit: 4 times in year 1, 4 times in year 2, 2 times in year 3, 1–2 times in years 4–5. - Chest X-ray: 2 times in year 1, 2 times in year 2; consider later imaging according to risk and care plan. - Abdominopelvic MRI/CT: 2 times in year 1, at 24 months, once at 36 months, and once at 60 months depending on risk and local practice. - For LVI-positive patients, some groups recommend more frequent early marker assessment and additional imaging. After adjuvant treatment: - Follow treatment-adapted protocols; markers/visits are generally more frequent in the first two years. - Continue survivorship-focused care after routine oncologic imaging ends.
                          • RELAPSE
                            • If relapse detected: stage-adapted salvage / metastatic GCT pathway
                              If relapse occurs, restage and route to stage-adapted salvage or metastatic GCT pathway. This stage I pathway should not embed a full metastatic treatment algorithm. If relapse is suspected: - Repeat AFP, beta-hCG, and LDH. - Confirm with appropriate imaging. - Define relapse pattern: retroperitoneal, thoracic, visceral, marker-only, local, or multifocal. - Confirm histology context: seminoma versus non-seminoma. - Assess prior adjuvant therapy: surveillance only, carboplatin, BEP x1, radiotherapy, or RPLND. - Evaluate timing of relapse. - Route to stage-adapted metastatic GCT management. - Consider referral to a germ cell tumor expert center, especially for relapse after adjuvant chemotherapy, late relapse, teratoma, somatic-type malignant transformation, or complex surgical questions. Do not manage relapse as a simple continuation of stage I surveillance.
                          • NUANCE
                            • Clinical nuance: avoid overtreatment; surveillance requires adherence; treatment decisions must include late toxicity
                              Avoid overtreatment, preserve cure, ensure surveillance adherence, and incorporate fertility and late toxicity into every decision. Key clinical nuances: 1. Surveillance is active management. It is appropriate only if the patient can adhere to visits, tumor markers, and imaging. 2. Cure is expected across strategies. The decision is mainly about relapse-risk reduction versus overtreatment and late toxicity. 3. Seminoma stage I: Surveillance is preferred for most. Carboplatin AUC 7 x1 is reasonable if adjuvant therapy is chosen. Radiotherapy should be avoided routinely. 4. NSGCT stage I: LVI is the key risk-adaptive variable. LVI-negative patients should generally be offered surveillance if compliant. LVI-positive patients should discuss BEP x1 or surveillance. 5. RPLND: Do not use routinely. Reserve for selected NSGCT patients in expert centers. 6. Markers: Persistent or rising AFP or beta-hCG after orchiectomy should not be treated as ordinary stage I disease. 7. Fertility and survivorship: Sperm banking, testosterone, psychosocial care, cardiovascular risk, hearing, neuropathy, renal function, pulmonary risk, and secondary malignancy risk should be considered before treatment selection. 8. Imaging: Minimize unnecessary radiation exposure. MRI can replace CT in experienced centers. FDG-PET/CT is not recommended for routine surveillance.
                  • YES
                    • LVI present / high risk: BEP x1 preferred / adjuvant option or surveillance
                      Discuss BEP x1 as preferred adjuvant option or surveillance after balanced counseling. For clinical stage I non-seminoma with lymphovascular invasion, relapse risk is higher. Preferred adjuvant option if treatment is chosen: - BEP x1. Alternative: - Surveillance remains acceptable if the patient declines adjuvant chemotherapy and can comply with strict follow-up. Clinical framing: - LVI increases relapse risk. - BEP x1 reduces relapse risk to very low levels but adds acute and potential long-term toxicity. - Shared decision-making should include fertility, pulmonary risk, renal function, neuropathy, hearing, cardiovascular risk, work/life logistics, and patient values. Before BEP x1: - Confirm normalized markers. - Confirm no metastatic disease. - CBC. - Renal and hepatic function. - Baseline pulmonary assessment and bleomycin fitness. - Fertility counseling and sperm banking. - Review smoking history and pulmonary comorbidity.
                      • SELECTED
                        • RPLND: highly selected patients only; expert / high-volume center
                          Consider nerve-sparing RPLND only in highly selected stage I non-seminoma patients in expert/high-volume centers. RPLND has a limited role in clinical stage I non-seminoma. Consider only in highly selected patients: - Contraindication to adjuvant chemotherapy. - Patient unwilling to accept surveillance. - Teratoma-predominant biology or pure postpubertal teratoma in selected cases. - Somatic-type malignant transformation arising in GCT. - Strong preference for surgical staging/management after expert counseling. Implementation: - Nerve-sparing approach when feasible. - Should be performed only by experienced surgeons in high-volume RPLND centers. - Discuss risk of ejaculatory dysfunction, surgical complications, need for further chemotherapy if pathologic stage II disease is found, and need for ongoing follow-up. Do not present RPLND as routine for most stage I NSGCT patients.
                          • FOLLOW-UP
                            • CARE PLAN
                              • Fertility, testosterone, prosthesis, psychosocial care, and survivorship plan
                                Address sperm banking, testosterone symptoms, prosthesis, psychosocial needs, late toxicity, cardiovascular risk, and survivorship plan. Survivorship begins at diagnosis. Before adjuvant therapy: - Discuss fertility goals. - Offer sperm banking before chemotherapy or radiotherapy when feasible. - Discuss testicular prosthesis if not already addressed. - Document baseline sexual health and testosterone-related symptoms when relevant. - Review psychosocial distress, body image, work, relationships, and financial/logistical barriers to follow-up. During follow-up: - Screen and manage hypertension. - Screen and manage hyperlipidemia. - Assess testosterone deficiency symptoms. - Encourage smoking cessation and healthy lifestyle. - Counsel on hearing, neuropathy, pulmonary symptoms, renal function, cardiovascular risk, and second malignancy risk when relevant to prior therapy. - Provide a written survivorship plan when transitioning out of specialist follow-up. Implementation note: This node is essential because many patients are young and have decades of life expectancy after cure.
                            • Follow-up framework: markers, clinical assessment, MRI/CT, minimize radiation exposure
                              Use risk- and treatment-adapted follow-up with markers, clinical assessment, MRI/CT, and radiation minimization. Follow-up should be adapted to histology, initial management, relapse risk, and prior treatment. General principles: - Use structured follow-up rather than informal monitoring. - Include tumor markers: AFP, beta-hCG, LDH. - Include clinical assessment. - Use abdominopelvic MRI or CT according to guideline schedule and local expertise. - Minimize radiation exposure when possible. - MRI can replace CT in experienced centers. - FDG-PET/CT is not recommended during surveillance. - After 5 years, routine imaging is generally not recommended; focus shifts to survivorship and symptom-triggered evaluation. Seminoma stage I minimal follow-up: - Markers ± visit: 2 times in year 1, 2 times in year 2, 2 times in year 3, once in years 4–5. - Abdominopelvic MRI/CT: 2 times in year 1, 2 times in year 2, once at 36 months, once at 60 months. Non-seminoma stage I on active surveillance: - Markers ± visit: 4 times in year 1, 4 times in year 2, 2 times in year 3, 1–2 times in years 4–5. - Chest X-ray: 2 times in year 1, 2 times in year 2; consider later imaging according to risk and care plan. - Abdominopelvic MRI/CT: 2 times in year 1, at 24 months, once at 36 months, and once at 60 months depending on risk and local practice. - For LVI-positive patients, some groups recommend more frequent early marker assessment and additional imaging. After adjuvant treatment: - Follow treatment-adapted protocols; markers/visits are generally more frequent in the first two years. - Continue survivorship-focused care after routine oncologic imaging ends.
                              • RELAPSE
                                • If relapse detected: stage-adapted salvage / metastatic GCT pathway
                                  If relapse occurs, restage and route to stage-adapted salvage or metastatic GCT pathway. This stage I pathway should not embed a full metastatic treatment algorithm. If relapse is suspected: - Repeat AFP, beta-hCG, and LDH. - Confirm with appropriate imaging. - Define relapse pattern: retroperitoneal, thoracic, visceral, marker-only, local, or multifocal. - Confirm histology context: seminoma versus non-seminoma. - Assess prior adjuvant therapy: surveillance only, carboplatin, BEP x1, radiotherapy, or RPLND. - Evaluate timing of relapse. - Route to stage-adapted metastatic GCT management. - Consider referral to a germ cell tumor expert center, especially for relapse after adjuvant chemotherapy, late relapse, teratoma, somatic-type malignant transformation, or complex surgical questions. Do not manage relapse as a simple continuation of stage I surveillance.
                              • NUANCE
                                • Clinical nuance: avoid overtreatment; surveillance requires adherence; treatment decisions must include late toxicity
                                  Avoid overtreatment, preserve cure, ensure surveillance adherence, and incorporate fertility and late toxicity into every decision. Key clinical nuances: 1. Surveillance is active management. It is appropriate only if the patient can adhere to visits, tumor markers, and imaging. 2. Cure is expected across strategies. The decision is mainly about relapse-risk reduction versus overtreatment and late toxicity. 3. Seminoma stage I: Surveillance is preferred for most. Carboplatin AUC 7 x1 is reasonable if adjuvant therapy is chosen. Radiotherapy should be avoided routinely. 4. NSGCT stage I: LVI is the key risk-adaptive variable. LVI-negative patients should generally be offered surveillance if compliant. LVI-positive patients should discuss BEP x1 or surveillance. 5. RPLND: Do not use routinely. Reserve for selected NSGCT patients in expert centers. 6. Markers: Persistent or rising AFP or beta-hCG after orchiectomy should not be treated as ordinary stage I disease. 7. Fertility and survivorship: Sperm banking, testosterone, psychosocial care, cardiovascular risk, hearing, neuropathy, renal function, pulmonary risk, and secondary malignancy risk should be considered before treatment selection. 8. Imaging: Minimize unnecessary radiation exposure. MRI can replace CT in experienced centers. FDG-PET/CT is not recommended for routine surveillance.
                      • FOLLOW-UP
                        • CARE PLAN
                          • Fertility, testosterone, prosthesis, psychosocial care, and survivorship plan
                            Address sperm banking, testosterone symptoms, prosthesis, psychosocial needs, late toxicity, cardiovascular risk, and survivorship plan. Survivorship begins at diagnosis. Before adjuvant therapy: - Discuss fertility goals. - Offer sperm banking before chemotherapy or radiotherapy when feasible. - Discuss testicular prosthesis if not already addressed. - Document baseline sexual health and testosterone-related symptoms when relevant. - Review psychosocial distress, body image, work, relationships, and financial/logistical barriers to follow-up. During follow-up: - Screen and manage hypertension. - Screen and manage hyperlipidemia. - Assess testosterone deficiency symptoms. - Encourage smoking cessation and healthy lifestyle. - Counsel on hearing, neuropathy, pulmonary symptoms, renal function, cardiovascular risk, and second malignancy risk when relevant to prior therapy. - Provide a written survivorship plan when transitioning out of specialist follow-up. Implementation note: This node is essential because many patients are young and have decades of life expectancy after cure.
                        • Follow-up framework: markers, clinical assessment, MRI/CT, minimize radiation exposure
                          Use risk- and treatment-adapted follow-up with markers, clinical assessment, MRI/CT, and radiation minimization. Follow-up should be adapted to histology, initial management, relapse risk, and prior treatment. General principles: - Use structured follow-up rather than informal monitoring. - Include tumor markers: AFP, beta-hCG, LDH. - Include clinical assessment. - Use abdominopelvic MRI or CT according to guideline schedule and local expertise. - Minimize radiation exposure when possible. - MRI can replace CT in experienced centers. - FDG-PET/CT is not recommended during surveillance. - After 5 years, routine imaging is generally not recommended; focus shifts to survivorship and symptom-triggered evaluation. Seminoma stage I minimal follow-up: - Markers ± visit: 2 times in year 1, 2 times in year 2, 2 times in year 3, once in years 4–5. - Abdominopelvic MRI/CT: 2 times in year 1, 2 times in year 2, once at 36 months, once at 60 months. Non-seminoma stage I on active surveillance: - Markers ± visit: 4 times in year 1, 4 times in year 2, 2 times in year 3, 1–2 times in years 4–5. - Chest X-ray: 2 times in year 1, 2 times in year 2; consider later imaging according to risk and care plan. - Abdominopelvic MRI/CT: 2 times in year 1, at 24 months, once at 36 months, and once at 60 months depending on risk and local practice. - For LVI-positive patients, some groups recommend more frequent early marker assessment and additional imaging. After adjuvant treatment: - Follow treatment-adapted protocols; markers/visits are generally more frequent in the first two years. - Continue survivorship-focused care after routine oncologic imaging ends.
                          • RELAPSE
                            • If relapse detected: stage-adapted salvage / metastatic GCT pathway
                              If relapse occurs, restage and route to stage-adapted salvage or metastatic GCT pathway. This stage I pathway should not embed a full metastatic treatment algorithm. If relapse is suspected: - Repeat AFP, beta-hCG, and LDH. - Confirm with appropriate imaging. - Define relapse pattern: retroperitoneal, thoracic, visceral, marker-only, local, or multifocal. - Confirm histology context: seminoma versus non-seminoma. - Assess prior adjuvant therapy: surveillance only, carboplatin, BEP x1, radiotherapy, or RPLND. - Evaluate timing of relapse. - Route to stage-adapted metastatic GCT management. - Consider referral to a germ cell tumor expert center, especially for relapse after adjuvant chemotherapy, late relapse, teratoma, somatic-type malignant transformation, or complex surgical questions. Do not manage relapse as a simple continuation of stage I surveillance.
                          • NUANCE
                            • Clinical nuance: avoid overtreatment; surveillance requires adherence; treatment decisions must include late toxicity
                              Avoid overtreatment, preserve cure, ensure surveillance adherence, and incorporate fertility and late toxicity into every decision. Key clinical nuances: 1. Surveillance is active management. It is appropriate only if the patient can adhere to visits, tumor markers, and imaging. 2. Cure is expected across strategies. The decision is mainly about relapse-risk reduction versus overtreatment and late toxicity. 3. Seminoma stage I: Surveillance is preferred for most. Carboplatin AUC 7 x1 is reasonable if adjuvant therapy is chosen. Radiotherapy should be avoided routinely. 4. NSGCT stage I: LVI is the key risk-adaptive variable. LVI-negative patients should generally be offered surveillance if compliant. LVI-positive patients should discuss BEP x1 or surveillance. 5. RPLND: Do not use routinely. Reserve for selected NSGCT patients in expert centers. 6. Markers: Persistent or rising AFP or beta-hCG after orchiectomy should not be treated as ordinary stage I disease. 7. Fertility and survivorship: Sperm banking, testosterone, psychosocial care, cardiovascular risk, hearing, neuropathy, renal function, pulmonary risk, and secondary malignancy risk should be considered before treatment selection. 8. Imaging: Minimize unnecessary radiation exposure. MRI can replace CT in experienced centers. FDG-PET/CT is not recommended for routine surveillance.
tosprivacyEuropean Association of Urology. EAU Guidelines on Testicular Cancer: Disease Management. 2026.European Association of Urology. EAU Guidelines on Testicular Cancer: Follow-up After Curative Therapy. 2026.Oliver RTD, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366:293-300.Joffe JK, Cafferty FH, Murphy L, et al. Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: TRISST trial. J Clin Oncol. 2022.